ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0328

From Patient Needs to Platform Design: Using Patient Preference to Guide the Development of a Post-Viral Fibromyalgia Management App

Marc Blanchard1, Pedro Ming Azevedo2, Tiffany Prétat2, Cinja Koller2 and Thomas Hügle3, 1Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University Lausanne, Lausanne, Switzerland, 2Lausanne University Hospital, Lausanne, Switzerland, 3Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland

Meeting: ACR Convergence 2023

Keywords: fibromyalgia, Intervention, Surveys

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0325–0344) Patient Outcomes, Preferences, & Attitudes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Post-viral fibromyalgia is a chronic condition that can develop in individuals following a viral infection, such as COVID-19. Recent studies have shown that approximately 30% of post-COVID19 patients satisfy the ACR criteria for fibromyalgia, experiencing symptoms such as chronic fatigue, widespread pain, sleep impairment, anxiety and depression.

Digital health interventions have demonstrated efficacy by providing disease monitoring, management and multimodal interventions to chronic pain patients. However, the widespread adoption and adherence to these interventions remain an obstacle. To address these challenges, this study aimed to develop a patient-centered digital health management app tailored specifically for post-viral fibromyalgia patients. By incorporating patient preferences through surveys and conducting usability testing, the study sought to enhance the usability of the app and the engagement of patients. Consequently, improving self-management, leading to improved patient outcomes and a better quality of life.

Methods: This study employed an explanatory design. Patient preference surveys were conducted among individuals recruited from “Long-COVID Schweiz”, a post-COVID19 patients association. Usability testing was run with post-viral fibromyalgia patients that were enrolled in the multimodal care program for chronic pain management at the University Hospital of Lausanne (Switzerland).

Data collected from surveys consisted of qualitative preference data related to functional design, interactions with the app, patient reported outcomes, type of monitored data and expected content. Usability testing data under the form of notes, interviews and patients’ feedback was collected by observing patients using the newly developed prototype.

Results: The frontend design of the app is shown in Figure 1. Among the 53 patients who responded to patient preference surveys, 90% preferred a regular symptoms list questionnaire over a chatbot to collect patient reported outcomes. Longitudinal symptom evaluation is shown in the “my result” section. 81% of patients expressed their wish that their symptoms are displayed with a benchmark of all other patients and to learn what has helped other patients with similar symptoms. A majority of them were also interested in links to patient communities (63%). Therefore, an anonymized discussion forum has been added. Patients preferred active training programs (63%) and information (59%) over interactive and gamified content (15%).

Among the 6 patients who participated in the usability testing, only 2 showed sufficient understanding of the functionalities and managed to navigate through the app without additional help, revealing the importance of the onboarding process.

Conclusion: Patient preference surveys guided the development of a patient-centric digital health solution, while usability testing identified issues with the onboarding process, requiring further study to investigate the impact of the onboarding on patient adoption and ultimately enhance engagement.

Supporting image 1

Figure 1: POCOS user interface (app): Left side: ‘How are you?’, with electronic patient reported outcomes and activity. Middle: ‘My result’, with monitoring of symptom’s activity and health conditions. Right side: ‘Act & Advice’, with personalized training program, adapted to the user’s symptoms.


Disclosures: M. Blanchard: Atreon SA, 8; P. Ming Azevedo: None; T. Prétat: None; C. Koller: None; T. Hügle: Atreon SA, 8, Curmed, 9, Eli Lilly, 6, Fresenius Kabi, 2, 5, Galapagos, 6, GlaxoSmithKlein(GSK), 6, Janssen, 6, Merck/MSD, 6, Pfizer, 6.

To cite this abstract in AMA style:

Blanchard M, Ming Azevedo P, Prétat T, Koller C, Hügle T. From Patient Needs to Platform Design: Using Patient Preference to Guide the Development of a Post-Viral Fibromyalgia Management App [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/from-patient-needs-to-platform-design-using-patient-preference-to-guide-the-development-of-a-post-viral-fibromyalgia-management-app/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/from-patient-needs-to-platform-design-using-patient-preference-to-guide-the-development-of-a-post-viral-fibromyalgia-management-app/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology